1		DRUG LAW AMEND	MENTS
2		2010 GENERAL SESS	SION
3		STATE OF UTAH	Ι
4		Chief Sponsor: Trisha	S. Beck
5		Senate Sponsor: Curtis S	. Bramble
6 7	Cosponsors: Bradley M. Daw	Paul Ray Phil Riesen	Stephen E. Sandstrom Evan J. Vickers
8			
9	LONG TITLE		
10	<b>General Description:</b>		
11	This bill modifies Tit	tle 58, Chapter 37, Utah Contro	lled Substances Act, regarding
12	Schedule IV substances.		
13	<b>Highlighted Provisions:</b>		
14	This bill:		
15	<ul><li>adds carisoprodol</li></ul>	, which has the brand name of	Soma, as a Schedule IV drug.
16	Monies Appropriated in th	is Bill:	
17	None		
18	Other Special Clauses:		
19	None		
20	<b>Utah Code Sections Affecte</b>	ed:	
21	AMENDS:		
22	<b>58-37-4</b> , as last amen	ded by Laws of Utah 2006, Cha	apter 8
23			
24	Be it enacted by the Legislate	ure of the state of Utah:	
25	Section 1. Section 58	8-37-4 is amended to read:	
26	<b>58-37-4.</b> Schedules	of controlled substances So	chedules I through V Findings
27	required Specific substar	nces included in schedules.	
28	(1) There are establish	shed five schedules of controlle	ed substances known as Schedules

I, II, III, IV, and V which shall consist of substances listed in this section.

30	(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
31	the official name, common or usual name, chemical name, or brand name designated:
32	(a) Schedule I:
33	(i) Unless specifically excepted or unless listed in another schedule, any of the
34	following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
35	ethers, when the existence of the isomers, esters, ethers, and salts is possible within the
36	specific chemical designation:
37	(A) Acetyl-alpha-methylfentanyl
38	(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
39	(B) Acetylmethadol;
40	(C) Allylprodine;
41	(D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
42	levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
43	(E) Alphameprodine;
44	(F) Alphamethadol;
45	(G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
46	propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
47	(H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
48	piperidinyl]-N-phenylpropanamide);
49	(I) Benzethidine;
50	(J) Betacetylmethadol;
51	(K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
52	piperidinyl]-N-phenylpropanamide);
53	(L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
54	phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
55	(M) Betameprodine;
56	(N) Betamethadol;
57	(O) Betaprodine;

58	(P) Clonitazene;
59	(Q) Dextromoramide;
60	(R) Diampromide;
61	(S) Diethylthiambutene;
62	(T) Difenoxin;
63	(U) Dimenoxadol;
64	(V) Dimepheptanol;
65	(W) Dimethylthiambutene;
66	(X) Dioxaphetyl butyrate;
67	(Y) Dipipanone;
68	(Z) Ethylmethylthiambutene;
69	(AA) Etonitazene;
70	(BB) Etoxeridine;
71	(CC) Furethidine;
72	(DD) Hydroxypethidine;
73	(EE) Ketobemidone;
74	(FF) Levomoramide;
75	(GG) Levophenacylmorphan;
76	(HH) Morpheridine;
77	(II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
78	(JJ) Noracymethadol;
79	(KK) Norlevorphanol;
80	(LL) Normethadone;
81	(MM) Norpipanone;
82	(NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
83	propanamide;
84	(OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
85	(PP) Phenadoxone;

86	(QQ) Phenampromide;
87	(RR) Phenomorphan;
88	(SS) Phenoperidine;
89	(TT) Piritramide;
90	(UU) Proheptazine;
91	(VV) Properidine;
92	(WW) Propiram;
93	(XX) Racemoramide;
94	(YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
95	(ZZ) Tilidine;
96	(AAA) Trimeperidine;
97	(BBB) 3-methylfentanyl, including the optical and geometric isomers
98	(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
99	(CCC) 3-methylthiofentanyl
100	(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenyl propanamide).
101	(ii) Unless specifically excepted or unless listed in another schedule, any of the
102	following opium derivatives, their salts, isomers, and salts of isomers when the existence of
103	the salts, isomers, and salts of isomers is possible within the specific chemical designation:
104	(A) Acetorphine;
105	(B) Acetyldihydrocodeine;
106	(C) Benzylmorphine;
107	(D) Codeine methylbromide;
108	(E) Codeine-N-Oxide;
109	(F) Cyprenorphine;
110	(G) Desomorphine;
111	(H) Dihydromorphine;
112	(I) Drotebanol;
113	(J) Etorphine (except hydrochloride salt);

114	(K) Heroin;
115	(L) Hydromorphinol;
116	(M) Methyldesorphine;
117	(N) Methylhydromorphine;
118	(O) Morphine methylbromide;
119	(P) Morphine methylsulfonate;
120	(Q) Morphine-N-Oxide;
121	(R) Myrophine;
122	(S) Nicocodeine;
123	(T) Nicomorphine;
124	(U) Normorphine;
125	(V) Pholcodine; and
126	(W) Thebacon.
127	(iii) Unless specifically excepted or unless listed in another schedule, any material,
128	compound, mixture, or preparation which contains any quantity of the following
129	hallucinogenic substances, or which contains any of their salts, isomers, and salts of isomers
130	when the existence of the salts, isomers, and salts of isomers is possible within the specific
131	chemical designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical,
132	position, and geometric isomers:
133	(A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
134	$\alpha$ -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; $\alpha$ -ET; and AET;
135	(B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
136	4-bromo-2,5-dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA;
137	(C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
138	2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
139	(D) 2,5-dimethoxyamphetamine, some trade or other names:
140	2,5-dimethoxy-α-methylphenethylamine; 2,5-DMA;

(E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;

142	(F) 4-methoxyamphetamine, some trade or other names:
143	4-methoxy-α-methylphenethylamine; paramethoxyamphetamine, PMA;
144	(G) 5-methoxy-3,4-methylenedioxyamphetamine;
145	(H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
146	4-methyl-2,5-dimethoxy-α-methylphenethylamine; "DOM"; and "STP";
147	(I) 3,4-methylenedioxy amphetamine;
148	(J) 3,4-methylenedioxymethamphetamine (MDMA);
149	(K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
150	alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
151	(L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
152	N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
153	(M) 3,4,5-trimethoxy amphetamine;
154	(N) Bufotenine, some trade and other names:
155	$3\hbox{-}(\beta\hbox{-Dimethylaminoethyl})\hbox{-}5\hbox{-hydroxyindole};\ 3\hbox{-}(2\hbox{-dimethylaminoethyl})\hbox{-}5\hbox{-indolol};\ N,$
156	N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
157	(O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
158	(P) Dimethyltryptamine, some trade or other names: DMT;
159	(Q) Ibogaine, some trade and other names:
160	7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
161	[5,4-b] indole; Tabernanthe iboga;
162	(R) Lysergic acid diethylamide;
163	(S) Marijuana;
164	(T) Mescaline;
165	(U) Parahexyl, some trade or other names:
166	3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
167	(V) Peyote, meaning all parts of the plant presently classified botanically as
168	Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
169	any part of such plant, and every compound, manufacture, salts, derivative, mixture, or

170 preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12)); 171 (W) N-ethyl-3-piperidyl benzilate; (X) N-methyl-3-piperidyl benzilate; 172 173 (Y) Psilocybin; 174 (Z) Psilocyn; 175 (AA) Tetrahydrocannabinols, synthetic equivalents of the substances contained in the 176 plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, 177 and their isomers with similar chemical structure and pharmacological activity such as the 178 following:  $\Delta 1$  cis or trans tetrahydrocannabinol, and their optical isomers  $\Delta 6$  cis or trans 179 tetrahydrocannabinol, and their optical isomers  $\Delta 3.4$  cis or trans tetrahydrocannabinol, and its 180 optical isomers, and since nomenclature of these substances is not internationally 181 standardized, compounds of these structures, regardless of numerical designation of atomic 182 positions covered; 183 (BB) Ethylamine analog of phencyclidine, some trade or other names: 184 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, 185 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE; (CC) Pyrrolidine analog of phencyclidine, some trade or other names: 186 187 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP; 188 (DD) Thiophene analog of phencyclidine, some trade or other names: 189 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and 190 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy. 191 (iv) Unless specifically excepted or unless listed in another schedule, any material 192 compound, mixture, or preparation which contains any quantity of the following substances 193 having a depressant effect on the central nervous system, including its salts, isomers, and salts 194 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the 195 specific chemical designation: 196 (A) Mecloqualone; and 197 (B) Methaqualone.

198	(v) Any material, compound, mixture, or preparation containing any quantity of the
199	following substances having a stimulant effect on the central nervous system, including their
200	salts, isomers, and salts of isomers:
201	(A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
202	4,5-dihydro-5-phenyl-2-oxazolamine;
203	(B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
204	alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
205	(C) Fenethylline;
206	(D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
207	alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
208	alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
209	methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts
210	of optical isomers;
211	(E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
212	(F) N-ethylamphetamine; and
213	(G) N,N-dimethylamphetamine, also known as
214	N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
215	(vi) Any material, compound, mixture, or preparation which contains any quantity of
216	the following substances, including their optical isomers, salts, and salts of isomers, subject to
217	temporary emergency scheduling:
218	(A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
219	(B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
220	(vii) Unless specifically excepted or unless listed in another schedule, any material,
221	compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
222	(gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
223	(b) Schedule II:
224	(i) Unless specifically excepted or unless listed in another schedule, any of the
225	following substances whether produced directly or indirectly by extraction from substances of

vegetable origin, or independently by means of chemical synthesis, or by a combination of

226

253

227 extraction and chemical synthesis: (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or 228 229 opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and 230 naltrexone, and their respective salts, but including: 231 (I) Raw opium; 232 (II) Opium extracts; 233 (III) Opium fluid; 234 (IV) Powdered opium; 235 (V) Granulated opium; (VI) Tincture of opium; 236 237 (VII) Codeine; 238 (VIII) Ethylmorphine; 239 (IX) Etorphine hydrochloride; 240 (X) Hydrocodone; 241 (XI) Hydromorphone; 242 (XII) Metopon; 243 (XIII) Morphine; 244 (XIV) Oxycodone; 245 (XV) Oxymorphone; and 246 (XVI) Thebaine; 247 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or 248 identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these 249 substances may not include the isoquinoline alkaloids of opium; 250 (C) Opium poppy and poppy straw; (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and 251 252 any salt, compound, derivative, or preparation which is chemically equivalent or identical with

any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,

254 and salts of isomers and derivatives, whether derived from the coca plant or synthetically 255 produced, except the substances may not include decocainized coca leaves or extraction of 256 coca leaves, which extractions do not contain cocaine or ecgonine; and 257 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in 258 either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium 259 poppy. 260 (ii) Unless specifically excepted or unless listed in another schedule, any of the 261 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and 262 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the 263 specific chemical designation, except dextrorphan and levopropoxyphene: (A) Alfentanil; 264 265 (B) Alphaprodine; 266 (C) Anileridine; 267 (D) Bezitramide; 268 (E) Bulk dextropropoxyphene (nondosage forms); 269 (F) Carfentanil; 270 (G) Dihydrocodeine; 271 (H) Diphenoxylate; 272 (I) Fentanyl; 273 (J) Isomethadone; 274 (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM: 275 276 (L) Levomethorphan; 277 (M) Levorphanol; 278 (N) Metazocine; 279 (O) Methadone; 280 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane; 281 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic

282	acid;
283	(R) Pethidine (meperidine);
284	(S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
285	(T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
286	(U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
287	(V) Phenazocine;
288	(W) Piminodine;
289	(X) Racemethorphan;
290	(Y) Racemorphan;
291	(Z) Remifentanil; and
292	(AA) Sufentanil.
293	(iii) Unless specifically excepted or unless listed in another schedule, any material,
294	compound, mixture, or preparation which contains any quantity of the following substances
295	having a stimulant effect on the central nervous system:
296	(A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
297	(B) Methamphetamine, its salts, isomers, and salts of its isomers;
298	(C) Phenmetrazine and its salts; and
299	(D) Methylphenidate.
300	(iv) Unless specifically excepted or unless listed in another schedule, any material,
301	compound, mixture, or preparation which contains any quantity of the following substances
302	having a depressant effect on the central nervous system, including its salts, isomers, and salts
303	of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
304	specific chemical designation:
305	(A) Amobarbital;
306	(B) Glutethimide;
307	(C) Pentobarbital;
308	(D) Phencyclidine;
309	(E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and

310	1-piperidinocyclonexanecarbonitrile (PCC); and
311	(F) Secobarbital.
312	(v) (A) Unless specifically excepted or unless listed in another schedule, any material,
313	compound, mixture, or preparation which contains any quantity of Phenylacetone.
314	(B) Some of these substances may be known by trade or other names:
315	phenyl-2-propanone[-]; P2P; benzyl methyl ketone[-]; and methyl benzyl ketone.
316	(vi) Nabilone, another name for nabilone:
317	(±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
318	6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
319	(c) Schedule III:
320	(i) Unless specifically excepted or unless listed in another schedule, any material,
321	compound, mixture, or preparation which contains any quantity of the following substances
322	having a stimulant effect on the central nervous system, including its salts, isomers whether
323	optical, position, or geometric, and salts of the isomers when the existence of the salts,
324	isomers, and salts of isomers is possible within the specific chemical designation:
325	(A) Those compounds, mixtures, or preparations in dosage unit form containing any
326	stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
327	listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
328	Code of Federal Regulations, and any other drug of the quantitive composition shown in that
329	list for those drugs or which is the same except that it contains a lesser quantity of controlled
330	substances;
331	(B) Benzphetamine;
332	(C) Chlorphentermine;
333	(D) Clortermine; and
334	(E) Phendimetrazine.
335	(ii) Unless specifically excepted or unless listed in another schedule, any material,
336	compound, mixture, or preparation which contains any quantity of the following substances

having a depressant effect on the central nervous system:

338	(A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
339	pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
340	which are not listed in any schedule;
341	(B) Any suppository dosage form containing amobarbital, secobarbital, or
342	pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
343	Administration for marketing only as a suppository;
344	(C) Any substance which contains any quantity of a derivative of barbituric acid or
345	any salt of any of them;
346	(D) Chlorhexadol;
347	(E) Buprenorphine;
348	(F) Any drug product containing gamma hydroxybutyric acid, including its salts,
349	isomers, and salts of isomers, for which an application is approved under the federal Food,
350	Drug, and Cosmetic Act, Section 505;
351	(G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
352	± -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
353	(H) Lysergic acid;
354	(I) Lysergic acid amide;
355	(J) Methyprylon;
356	(K) Sulfondiethylmethane;
357	(L) Sulfonethylmethane;
358	(M) Sulfonmethane; and
359	(N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
360	tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
361	2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
362	4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
363	flupyrazapon.
364	(iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in
365	a U.S. Food and Drug Administration approved drug product, some other names for

366	dronabinol
500	uronaomoi

367 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta-9-(trans)-tetrahydrocannabinol.

- (iv) Nalorphine.
- (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
- (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
- (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
- (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
- (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;
- (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
- (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;
- (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and

394 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams 395 with one or more active, non-narcotic ingredients in recognized therapeutic amounts. 396 (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids 397 including any of the following or any isomer, ester, salt, or derivative of the following that 398 promotes muscle growth: 399 (A) Boldenone; 400 (B) Chlorotestosterone (4-chlortestosterone); 401 (C) Clostebol; 402 (D) Dehydrochlormethyltestosterone; 403 (E) Dihydrotestosterone (4-dihydrotestosterone); 404 (F) Drostanolone; 405 (G) Ethylestrenol; 406 (H) Fluoxymesterone; 407 (I) Formebulone (formebolone); 408 (J) Mesterolone; 409 (K) Methandienone; 410 (L) Methandranone; 411 (M) Methandriol; 412 (N) Methandrostenolone; 413 (O) Methenolone; 414 (P) Methyltestosterone; 415 (Q) Mibolerone; 416 (R) Nandrolone; 417 (S) Norethandrolone; 418 (T) Oxandrolone; 419 (U) Oxymesterone; 420 (V) Oxymetholone; 421 (W) Stanolone;

422	(X) Stanozolol;
423	(Y) Testolactone;
424	(Z) Testosterone; and
425	(AA) Trenbolone.
426	(vii) Anabolic steroids expressly intended for administration through implants to cattle
427	or other nonhuman species, and approved by the Secretary of Health and Human Services for
428	use, may not be classified as a controlled substance.
429	(d) Schedule IV:
430	(i) Unless specifically excepted or unless listed in another schedule, any material,
431	compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
432	less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.
433	(ii) Unless specifically excepted or unless listed in another schedule, any material,
434	compound, mixture, or preparation which contains any quantity of the following substances,
435	including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
436	salts of isomers is possible within the specific chemical designation:
437	(A) Alprazolam;
438	(B) Barbital;
439	(C) Bromazepam;
440	(D) Butorphanol;
441	(E) Camazepam;
442	(F) Carisoprodol;
443	[ <del>(F)</del> ] <u>(G)</u> Chloral betaine;
444	[ <del>(G)</del> ] <u>(H)</u> Chloral hydrate;
445	[(H)] (I) Chlordiazepoxide;
446	[ <del>(I)</del> ] <u>(J)</u> Clobazam;
447	[H] (K) Clonazepam;
448	[(K)] (L) Clorazepate;
449	[ <del>(L)</del> ] (M) Clotiazepam;

450	[ <del>(M)</del> ] <u>(N)</u> Cloxazolam;
451	[(N)] (O) Delorazepam;
452	[ <del>(O)</del> ] <u>(P)</u> Diazepam;
453	[(P)] (Q) Dichloralphenazone;
454	$\left[\frac{(Q)}{R}\right]$ (R) Estazolam;
455	[(R)] (S) Ethchlorvynol;
456	[(S)] (T) Ethinamate;
457	[(T)] (U) Ethyl loflazepate;
458	[(U)] (V) Fludiazepam;
459	[ <del>(V)</del> ] <u>(W)</u> Flunitrazepam;
460	[(W)](X) Flurazepam;
461	[(X)] $(Y)$ Halazepam;
462	[(Y)] (Z) Haloxazolam;
463	[ <del>(Z)</del> ] (AA) Ketazolam;
464	[(AA)] (BB) Loprazolam;
465	[(BB)] (CC) Lorazepam;
466	[(CC)] (DD) Lormetazepam;
467	[ <del>(DD)</del> ] <u>(EE)</u> Mebutamate;
468	[(EE)] (FF) Medazepam;
469	[(FF)] (GG) Meprobamate;
470	[ <del>(GG)</del> ] (HH) Methohexital;
471	[(HH)] (II) Methylphenobarbital (mephobarbital)
472	[ <del>(II)</del> ] <u>(JJ)</u> Midazolam;
473	[(JJ)] (KK) Nimetazepam;
474	[(KK)] (LL) Nitrazepam;
475	[(LL)] (MM) Nordiazepam;
476	[(MM)] (NN) Oxazepam;
477	[ <del>(NN)</del> ] <u>(OO)</u> Oxazolam;

```
478
               [(OO)] (PP) Paraldehyde;
479
              [(PP)] (QQ) Pentazocine;
480
              [<del>(QQ)</del>] (RR) Petrichloral;
481
              [(RR)] (SS) Phenobarbital;
482
              [(SS)] (TT) Pinazepam;
483
              [(TT)] (UU) Prazepam;
484
               [(UU)] (VV) Quazepam;
485
              [<del>(VV)</del>] (WW) Temazepam;
486
              [(WW)] (XX) Tetrazepam;
487
              [(XX)](YY) Triazolam;
488
              [(YY)] (ZZ) Zaleplon; and
489
              [(ZZ)] (AAA) Zolpidem.
490
              (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
491
       any quantity of the following substances, including its salts, isomers whether optical, position,
492
       or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
493
       isomers is possible.
494
               (iv) Unless specifically excepted or unless listed in another schedule, any material,
495
       compound, mixture, or preparation which contains any quantity of the following substances
496
       having a stimulant effect on the central nervous system, including its salts, isomers whether
497
       optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,
498
       isomers, and salts of isomers is possible within the specific chemical designation:
499
              (A) Cathine ((+)-norpseudoephedrine):
500
              (B) Diethylpropion;
501
              (C) Fencamfamine;
502
              (D) Fenproprex;
503
              (E) Mazindol;
504
               (F) Mefenorex;
505
               (G) Modafinil;
```

506	(H) Pemoline, including organometallic complexes and chelates thereof;
507	(I) Phentermine;
508	(J) Pipradrol;
509	(K) Sibutramine; and
510	(L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
511	(v) Unless specifically excepted or unless listed in another schedule, any material,
512	compound, mixture, or preparation which contains any quantity of dextropropoxyphene
513	(alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
514	(e) Schedule V: Any compound, mixture, or preparation containing any of the
515	following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous
516	base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in
517	sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal
518	qualities other than those possessed by the narcotic drug alone:
519	(i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
520	(ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
521	grams;
522	(iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
523	grams;
524	(iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
525	atropine sulfate per dosage unit;
526	(v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
527	(vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
528	atropine sulfate per dosage unit; and
529	(vii) unless specifically exempted or excluded or unless listed in another schedule, any
530	material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant
531	effect on the central nervous system, including its salts, isomers, and salts of isomers.